Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Rhythm Pharmaceuticals Inc. is currently navigating the prosecution of 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These active matters are distributed across 2 distinct examiners, indicating a variety of perspectives reviewing the company's intellectual property. The prosecution efforts are also spread across 2 distinct art units, which suggests that the technical scope of the portfolio spans multiple specialized examination groups.
LEE, JIA-HAI is identified as the busiest examiner for the company, currently managing 2 pending office actions. This means that a significant portion of the company's 3 pending office actions is under the review of a single individual. For a practitioner, this concentration highlights the importance of understanding the specific examination style of LEE, JIA-HAI, as this examiner's decisions will impact the majority of the current pending workload.
The distribution of 3 pending actions across 2 distinct art units and 2 distinct examiners reflects a focused but slightly diversified prosecution strategy. While the company must manage relationships with multiple examiners, the primary focus remains on the 2 pending office actions assigned to LEE, JIA-HAI. This structure requires a balanced approach to prosecution that addresses both the specific requirements of the busiest examiner and the unique demands of the other examiner involved.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, JIA-HAI | 2 | 49.0% | +46.9% |
| CHANDRA, GYAN | 1 | 71.3% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18028117 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHANDRA, GYAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 15764730 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | LEE, JIA-HAI | 99d overdue |
| 17712752 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | LEE, JIA-HAI | 86d overdue |
| 18028117 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHANDRA, GYAN | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18028117 | METHODS OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | CHANDRA, GYAN | 1674 | §103§112 | Non-Final OA | — | Pending | Mar 23, 2023 |
| 17712752 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | LEE, JIA-HAI | 1658 | §103DP | Final Rejection | 86d overdue | Pending | Apr 04, 2022 |
| 15764730 | METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS | LEE, JIA-HAI | 1658 | §103DP | Final Rejection | 99d overdue | Pending | Mar 29, 2018 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRhythm Pharmaceuticals Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jia-Hai Lee has the most, with 2 of Rhythm Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
